Vertex Pharmaceuticals Inc (VRTX) — Cash Flow-to-Debt Ratio
Vertex Pharmaceuticals Inc (VRTX) has a Cash Flow-to-Debt Ratio of 0.20x as of March 2026, meaning its operating cash flow of $1.43 Billion could theoretically repay 0% of its total liabilities ($7.12 Billion) in one year. Explore Vertex Pharmaceuticals Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Vertex Pharmaceuticals Inc Cash Flow-to-Debt Ratio (1991–2025)
Historical debt coverage capacity for Vertex Pharmaceuticals Inc across 35 annual periods. Also explore Vertex Pharmaceuticals Inc (VRTX) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Vertex Pharmaceuticals Inc (1991–2025)
Year-by-year debt coverage analysis for Vertex Pharmaceuticals Inc. For market capitalisation and broader financial context, see how much is Vertex Pharmaceuticals Inc worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.49x | $3.63 Billion | $7.48 Billion | ▲ +703.8% |
| 2024 | -0.08x | $-492.60 Million | $6.12 Billion | ▼ -111.7% |
| 2023 | 0.69x | $3.54 Billion | $5.15 Billion | ▼ -29.5% |
| 2022 | 0.97x | $4.13 Billion | $4.24 Billion | ▲ +22.8% |
| 2021 | 0.79x | $2.64 Billion | $3.33 Billion | ▼ -25.3% |
| 2020 | 1.06x | $3.25 Billion | $3.06 Billion | ▲ +51.1% |
| 2019 | 0.70x | $1.57 Billion | $2.23 Billion | ▲ +0.2% |
| 2018 | 0.70x | $1.27 Billion | $1.81 Billion | ▲ +24.9% |
| 2017 | 0.56x | $844.94 Million | $1.50 Billion | ▲ +270.2% |
| 2016 | 0.15x | $236.10 Million | $1.56 Billion | ▲ +158.3% |
| 2015 | -0.26x | $-365.43 Million | $1.40 Billion | ▲ +37.2% |
| 2014 | -0.41x | $-513.20 Million | $1.24 Billion | ▼ -673.5% |
| 2013 | -0.05x | $-51.57 Million | $962.64 Million | ▼ -130.5% |
| 2012 | 0.18x | $267.84 Million | $1.52 Billion | ▲ +51.4% |
| 2011 | 0.12x | $143.74 Million | $1.24 Billion | ▲ +122.3% |
| 2010 | -0.52x | $-635.44 Million | $1.22 Billion | ▼ -4.5% |
| 2009 | -0.50x | $-427.59 Million | $859.14 Million | ▼ -63.0% |
| 2008 | -0.31x | $-226.48 Million | $741.61 Million | ▲ +60.1% |
| 2007 | -0.76x | $-252.48 Million | $330.18 Million | ▼ -1314.1% |
| 2006 | -0.05x | $-22.48 Million | $415.64 Million | ▲ +90.3% |
| 2005 | -0.56x | $-172.05 Million | $309.82 Million | ▼ -99.2% |
| 2004 | -0.28x | $-142.16 Million | $510.01 Million | ▲ +11.6% |
| 2003 | -0.32x | $-167.62 Million | $531.57 Million | ▼ -73.3% |
| 2002 | -0.18x | $-79.54 Million | $437.14 Million | ▼ -913.6% |
| 2001 | -0.02x | $-8.07 Million | $449.78 Million | ▲ +53.9% |
| 2000 | -0.04x | $-16.64 Million | $427.12 Million | ▲ +97.2% |
| 1999 | -1.37x | $-31.80 Million | $23.21 Million | ▲ +11.5% |
| 1998 | -1.55x | $-31.10 Million | $20.10 Million | ▼ -222.6% |
| 1997 | -0.48x | $-9.40 Million | $19.60 Million | ▲ +84.9% |
| 1996 | -3.17x | $-40.30 Million | $12.70 Million | ▼ -171.7% |
| 1995 | -1.17x | $-16.00 Million | $13.70 Million | ▲ +15.0% |
| 1994 | -1.37x | $-14.70 Million | $10.70 Million | ▼ -283.7% |
| 1993 | 0.75x | $8.60 Million | $11.50 Million | ▲ +200.2% |
| 1992 | -0.75x | $-5.30 Million | $7.10 Million | ▼ -46.3% |
| 1991 | -0.51x | $-2.50 Million | $4.90 Million | — |